Hypertrophy, hyperplasia and altered mucus secretion from the respiratory submucosal glands (SMG) are characteristics of airway diseases such as cystic fibrosis, asthma and chronic bronchitis. More commonly, hyper-secretion of the nasal SMGs contributes to allergic rhinitis and upper airway infection. Considering the role of these glands in disease states, there is a significant dearth in understanding the molecular signals that regulate SMG development and patterning. Due to the imperative role of FGF signalling during the development of other branched structures, we investigated the role of Fgf10 during initiation and branching morphogenesis of murine nasal SMGs. Fgf10 is expressed in the mesenchyme around developing SMGs while expression of its receptor Fgfr2 is seen within glandular epithelial cells. In the Fgf10 null embryo, Steno's gland and the maxillary sinus gland were completely absent while other neighbouring nasal glands showed normal duct elongation but defective branching. Interestingly, the medial nasal glands were present in Fgf10 homozygotes but missing in Fgfr2b mutants, with expression of Fgf7 specifically expressed around these developing glands, indicating that Fgf7 might compensate for loss of Fgf10 in this group of glands. Intriguingly the lateral nasal glands were only mildly affected by loss of FGF signalling, while these glands were missing in Eda mutant mice, where the Steno's and maxillary sinus gland developed as normal. This analysis reveals that regulation of nasal gland development is complex with different subsets of glands being regulated by different signalling pathways. This analysis helps shed light on the nasal gland defects observed in patients with hypohidrotic ectodermal dysplasia (HED) (defect EDA pathway) and LADD syndrome (defect FGFR2b pathway).
Introduction
Impaired mucus clearance and pulmonary obstruction are common symptoms of a number of life-threatening respiratory diseases. Mucus hyper-secretion by the submucosal glands (SMG) is an important etiological factor in asthma, chronic bronchitis and cystic fibrosis with SMG hyperplasia and mucous metaplasia common to all (Reid, 1960; Oppenheimer and Esterly 1975; Aikawa et al., 1992) . Hyper-secretion and abnormal mucociliary clearance leads to a build-up of mucus with a thick viscosity which can obstruct airways and increase bacterial lung infection, leading to premature death in severe cases (Oppenheimer and Esterly, 1975; Hoegger et al., 2014; Robinson and Bye, 2002) . More commonly, altered mucus secretion of the nasal glands, particularly the sinus glands, gives rise to chronic rhinosinusitis and infection of the upper airway tract (Peña et al., 2007; Wu et al., 2011) . Considering this significant involvement of SMGs in pulmonary diseases, research is lacking in the mechanisms modulating gland development and homeostasis. To understand the progression of airway disease, it is critical to elucidate the signalling factors and pathways required during SMG morphogenesis, and investigate if these mechanisms are defective in disease states.
The SMGs are found in the submucosal connective tissue beneath the respiratory epithelium (RE) of the conductive airways (Fig. 1) . The anterior nasal SMGs provide the first line of defence within the airway. The medial and lateral glands are found within the medial and lateral nasal walls respectively, while the sinus glands drain their secretions directly into the sinus cavity (Grüneberg, 1971; May and Tucker, 2015) (Fig. 1) . In humans, SMGs are further found within the submucosa between the cartilaginous rings of the distal airways, stretching throughout the trachea and bronchi (Borthwick et al., 1999; Sturgess and Imrie, 1982) . In mice, Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/developmentalbiology SMGs extend to the anterior trachea, where they are found at high density adjacent to the cricoid cartilage (CC) and develop no further than the sixth cartilaginous tracheal ring (Borthwick et al., 1999; Rawlins and Hogan, 2005) .
The SMGs develop through a process of branching morphogenesis. This process, common to other mammalian epithelial organs such as the mammary gland, salivary gland and lung, involves the formation of a single tube from an epithelial sheath that undergoes continual elongation and clefting to create a complex network of branched tubes and terminal buds. Cellular differentiation occurs within these structures to form ductal units within the branches, while end buds differentiate into functional units that transport liquid or gas. In SMGs, these distal functional units are composed of serous and mucous cells that produce airway mucus rich in mucins and bactericidal enzymes (Meyrick et al., 1969; Meyrick and Reid, 1970) .
Members of the fibroblast growth factor (FGFs) family of polypeptide proteins have been shown to be involved in branching morphogenesis of other organs such as the lung, salivary and lacrimal glands. The FGF family consists of 22 ligands (FGF1-FGF22) and four cell membrane-bound tyrosine kinase FGF receptors (FGFR1-FGFR4) (Ornitz and Itoh, 2001 ). The essential requirement for FGF10 and its receptor FGFR2b during lung morphogenesis is emphasised by the shared defects of both Fgf10 homozygous ( À / À) and Fgfr2b À / À mice, who die at birth due to agenesis of the lungs (Sekine et al., 1999; Min et al., 1998; De Moerlooze et al., 2000) . FGF10 and FGFR2b are also critical for salivary gland duct elongation and branching (Jaskoll et al., 2005; Steinberg et al., 2005) . The submandibular salivary gland fails to develop past the initial bud stage at embryonic day E12.5 in both Fgf10 À / À and Fgfr2b À / À mice, and salivary glands are hypoplastic and secrete a reduced volume of saliva in Fgf10 heterozygous (þ/ À ) adults . Mutations in FGF10 or its receptor FGFR2b, lead to Lacrimo Auriculo Dento Digital (LADD) syndrome (OMIM 149730) in humans. This anomaly is characterized by hypoplasia, atresia or aplasia of the salivary glands and the lacrimal glands of the eyes, and obstruction of the nasolacrimal duct (Shiang and Holmes, 1977; Inan et al., 2006) . A milder form of this disease, known as Aplasia of Lacrimal and Salivary Glands (ALSG) (OMIM 180920), gives rise to the same symptoms as LADD, most often including xerothalmia (dryness of the eye) and xerostomia (dry mouth) (Wiedemann, 1997; Milunsky et al., 1990) .
The Ectodysplasin A (EDA) pathway is also required for morphogenesis of many glandular structures (Mikkola, 2009) . A naturally occurring mutation in the EDA gene arises in the Tabby mouse, leading to defective hair, tooth and salivary gland development (Srivastava et al., 1997) . Investigation of the nasal SMGs in the Tabby mouse revealed absence of some of the nasal glands, while others, such as Steno's gland, the largest of the nasal glands, also known as the lateral nasal gland 1 (LNG1) (Fig. 1) , developed normally in the Tabby mouse (Grüneberg 1971) . mRNA expression of Edar, the receptor for EDA, was found in the tracheal respiratory epithelium during postnatal SMG development (Rawlins and Hogan, 2005) . The absence of tracheal SMGs were observed in both the adult Tabby mouse and postnatally in the Edaradd knockout mouse, which lacks an EDAR signalling adapter molecule, highlighting the requirement of the EDA signalling pathway in successful tracheal SMG morphogenesis (Rawlins and Hogan, 2005) . Human patients with hypohidrotic ectodermal dysplasia (HED) have developmental defects in teeth, hair and salivary glands caused by mutations in EDA, EDAR or EDARADD (Mikkola, 2009) . Respiratory difficulties and nasal gland defects have also been reported in HED patients with nasal dryness of the nasal mucosa, nasal crusting and abnormal nasal discharge all being symptoms of the disease (Al-Jassim and Swift, 1996; Dietz et al., 2013) .
In this study, we have investigated the requirement for FGF10/ FGFR2b and EDA signalling during the crucial stages of SMG development among the different nasal gland populations. We conclude that the Steno's gland and sinus glands are predominantly dependent on FGF10/FGFR2b signalling from initial stages of gland budding and elongation, while the medial and lateral glands require this pathway for later gland branching stages. It is suggested that the medial glands are reliant on FGF7/ FGFR2b signalling from early development while the lateral glands are more dependent on EDA-mediated signalling. Elucidating these heterogeneous signalling mechanisms will further our understanding in the complex organization and maintenance of these glands, in hopes to combat disease occurrence and progression.
Material and methods

Experimental animals
Fgf10-deficient mice were first generated by Min et al. (1998) 
Animal collection
For embryo collection, adult mice were mated in the late evening and a midnight mating was assumed. Midday of the day at which a vaginal plug was discovered was recorded as embryonic day (E) 0.5. For postnatal pup collection, the day female mice littered down was recorded as P0. Adult males and females were culled by exposure to rising levels of CO 2 gas. Primers used to detect wildtype Fgf10 locus were 5′-GAGGAAATGCTGCGCA-CAATGTATACTCGG-3′ (Fgf203 forward primer) and 5′-GGA-TACTGACACATTGTGCCTCAGCCTTTC-3′ (Fgf204 reverse primer) while the mutant Fgf10 locus was detected by primers 5′-GCTTGGGTGGAGAGGCTATTC-3′ (Fgf233 forward primer) and 5′-CAAGGTGAGATGACAGGAGATC-3′ (Fgf234 reverse primer) of the neo-cassette insert (Sekine et al., 1999) . Fgfr2b and Eda mutants were genotyped as previously described (Charles et al., 2009; De Moerlooze et al., 2000) .
Histological Staining and RNA in situ hybridisation
Upon collection, embryonic heads were fixed in 4% paraformaldehyde in PBS (PFA) overnight at 4°C. For tissue collected for in situ hybridisation procedures, all solutions used were diethylpyrocarbonate (DEPC) treated. Tissue was dehydrated in increasing methanol concentrations and left overnight at 4°C in Isopropanol (Sigma Aldrich). Samples were cleared in 1,2,3,4 Tetrahydronapthalene at RT, and embedded in paraffin wax. Alternative serial 9 mm sagittal sections were collected along the left/right axis through the entire embryonic head.
Paraffin embedded sections were dewaxed using Histoclear and rehydrated through an ethanol series. Craniofacial sections were stained using a Trichrome stain of 1% Alcian Blue, Ehrlich's Haematoxylin and 0.5% Sirius Red in saturated Picric Acid.
For in situ hybridisation of embryonic nasal tissue with digoxigenin or S35-labelled riboprobes, sections were deparaffinised and rehydrated in decreasing ethanol concentrations in DEPC treated PBS. In situ hybridisation technique was carried out using a modified Wilkinson protocol (Wilkinson, 1995 Tucker et al., 2000) cDNA plasmid vectors and gene inserts used for riboprobe generation have been previously described.
Results
Fgf10 and Fgfr2 are expressed during nasal gland development
To understand the role of the FGF pathway in nasal gland development the expression of Fgf10 and Fgfr2 was investigated during embryonic stages of gland initiation and branching morphogenesis. At E14.5, prior to the branching of the distal Steno's gland ( Fig. 2A) , Fgf10 expression was observed in the mesenchyme surrounding the extending Steno's duct (Fig. 2B) . Fgfr2 expression was found within the distal epithelial cells of the elongated Steno's duct at E14.5 (Fig. 2C) . During gland branching at E16.5 (Fig. 2D) , Fgf10 expression was apparent throughout the mesenchyme surrounding the end buds of the Steno's gland (Fig. 2E) , while Fgfr2 mRNA was evident within the epithelial cells of the gland buds (Fig. 2F) .
Fgf10 was expressed throughout the mesenchyme adjacent to the maxillary sinus gland (MSG) primordium at E14.5 ( Fig. 2G and H), with Fgfr2 expression observed within the maxillary sinus epithelium from which the MSG buds (Fig. 2I ). During MSG branching at E16.5 (Fig. 2J ), Fgf10 expression was maintained throughout the mesenchyme adjacent to the branching MSG end buds (Fig. 2K) . At this stage, Fgfr2 expression was lost within the maxillary sinus epithelium however it was apparent in the distal tips of the branching MSG end buds (Fig. 2L) .
At E14.5 the duct of LNG2 had begun its elongation through the middle conchal mesenchyme (Fig. S1A ) and the bud of LNG3 had emerged from the epithelium of the middle conchal lip (Fig. S1B ) (May and Tucker, 2015) . By E16.5, LNG2 and LNG3 were seen branching, close to the maxillary sinus cavity (Fig. S1C) . At E14.5, Fgf10 was expressed in the conchal mesenchyme surrounding both the extending LNG2 (Fig. S1D ) and the budding LNG3 (Fig. S1E) . At E16.5, Fgf10 was expressed throughout the mesenchyme surrounding the developing LNG end buds (Fig. S1F) . Fgfr2 was expressed in the ductal epithelial cells of the elongating LNG2 (Fig.  S1G ) and within the cells of the LNG3 bud (Fig. S1H ) at E14.5. As LNG2 and LNG3 were branching at E16.5, Fgfr2 was expressed within the end bud epithelial cells of LNG2 and LNG3 (Fig. S1I) . At E16.5, when the LNG4 duct was elongating beneath the nasal septum, Fgf10 was also expressed in the mesenchyme surrounding the extending duct with Fgfr2 within the ductal cells (not shown).
At E14.5, the duct of medial nasal gland (MNG)1 was seen to extend into the mesenchyme of the nasal septum (Fig. S2A) and by E16.5, the MNGs had branched adjacent to the vomeronasal organ (VNO) (Fig. S2B) . Fgf10 was expressed throughout the mesenchyme of the nasal septum at E14.5 when the MNG ducts were elongating (Fig. S2C) . At the branching stages of the MNGs at E16.5, Fgf10 expression surrounded the extending glandular branches (Fig. S2D) . Fgfr2 expression was noted in the epithelial cells of the extending MNG1 duct at E14.5 (Fig. S1E) and Fgfr2 was expressed within the gland buds at E16.5 (Fig. S1F) .
Fgf10 is critical for Steno's and MSG development
To define the role of Fgf10 in anterior nasal gland development, we analysed the gland phenotype in wildtype (WT), Fgf10 þ / À and Fgf10 À / À mice. At E12.5 the Steno's gland duct arises from the RE and invaginates into the mesenchyme of the middle concha. At this stage an epithelial pit was observed in WT mice (Fig. 3A) . By E17.5, the lumenized Steno's duct was observed through a frontal section of the nasal region (Fig. 3B) , and the majority of the elongated anterior nasal glands had branched, as evident in a more caudal sagittal section (Fig. 3C) . At E17.5, the MNGs had extensively branched throughout the nasal septum mesenchyme (Fig. 3D) .
In Fgf10 þ/ À mice, the epithelial invagination of the Steno's duct had formed at E12.5, similarly to WT mice (Fig. 3E) . At E17.5, the Steno's gland developed in Fgf10 þ/ À animals and its duct (Fig. 3F ) elongated to the correct location underneath the maxillary sinus (Fig. 3 -yellow) , however, the extent of branching was reduced (Fig. 3G) . Similarly, branching of the MSG, LNGs, and MNGs was also noticeably reduced in Fgf10 þ/ À mice ( Fig. 3G and H) compared to that observed in WTs.
In Fgf10 À / À embryos, no Steno's duct pit was apparent at .5, Fgf10 expression is found throughout the mesenchyme beneath the maxillary sinus epithelium in the location of where the Steno's gland will branch, while Fgfr2 is expressed in the distal epithelial cells of the Steno's duct (C). At E16.5 the Steno's gland is undergoing continual branching (D). Fgf10 is expressed in the mesenchyme surrounding the distal gland buds (E) and Fgfr2 is evident in the distal epithelial cells of the Steno's gland end buds (F). (G) Trichrome stained sagittal section of the MSG primordium at E14.5. Fgf10 is expressed throughout the mesenchyme surrounding the MSG primordium at E14.5 (H) and Fgfr2 mRNA is detected in the maxillary sinus epithelium, of which the MSG buds (I). By E16.5 when the MSG is branching (J), Fgf10 is expressed in the mesenchyme surrounding the branching MSG end buds (K). By E16.5, Fgfr2 expression is lost from the maxillary sinus epithelium but found within the distal end buds of the MSG (L). Yellow line ¼Steno's gland; blue line ¼ basement membrane of the maxillary sinus epithelium, red line ¼ MSG; orange line ¼ maxillary sinus lumen. Scale bar¼ 100 mm.
E12.5 (Fig. 3I ). This phenotype indicated that FGF10 signalling is critical for the initial invagination of the duct of the Steno's gland. By E17.5, complete absence of the Steno's duct (Fig. 3J ) and gland ( Fig. 3K -yellow asterisks) was observed in Fgf10 À/ À mice. Additionally, the MSG was absent with complete loss of Fgf10 (Fig. 3K -red asterisks). The LNGs were observed in Fgf10 À/ À mice at E17.5 (Fig. 3K) . Their ducts budded and elongated to the correct locations when compared to WT specimens, however branching of the distal glands was significantly reduced (Fig. 3K) . Furthermore, the MNGs were severely defective with truncated ducts and a considerable reduction in branching, following complete loss of Fgf10 (Fig. 3L ).
Fgfr2b is critical for Steno's gland, MSG, LNG4 and MNG development
Given that only a subset of glands failed to develop in Fgf10 mutants we decided to assess whether other FGF ligands, working through the same receptor as FGF10, were critical for development of the lateral and medial nasal glands. We therefore investigated the gland phenotype in Fgfr2b knockout mice at E18.5, when the majority of glands have extended and started to branch. Similarly to Fgf10 homozygous mutants, the Steno's gland and MSG were completely absent in Fgfr2b À / À mice (Fig. 4A-D) . The lateral nasal glands (LNG2,3,5) were also present as in the Fgf10 À/ À , but again with reduced branching (Fig. 4C-F and data not shown) . Unexpectedly, however, LNG4, which normally forms underneath the nasal cartilage capsule, was completely absent in Fgfr2b deficient animals at E18.5 ( Fig. 4G-H) . Additionally, unlike the Fgf10 À / À phenotype, the MNGs were also completely absent with loss of Fgfr2b (Fig. 4I-J) . This indicates that other FGFs that bind to FGFR2b are required for MNG and LNG4 duct elongation.
Fgf7 is expressed during medial nasal gland development
Considering the absence of the MNGs in the Fgfr2b À / À mouse, yet the presence of MNG ducts and primary branches in the Fgf10 homozygous embryo, we assessed the expression of Fgf7 during normal gland development. FGF7 is closely related to FGF10 and also binds to FGFR2b with high affinity (Zhang et al., 2006) . Fgf7 was not found in the mesenchyme surrounding the Steno's gland during any of the duct elongation stages (Fig. 5A ) or gland branching (Fig. 5B) . Fgf7 expression was observed surrounding the nasolacrimal duct (NLD) and this was used as a positive control of gene expression (Fig. 5B inset image) . No Fgf7 expression was associated with LNG or MSG development (Fig. 5C-F) . Fgf7 expression was observed throughout the septal mesenchyme at E14.5, close to where the medial nasal glands were forming (Fig. 5G) . As the MNG ducts were elongating Fgf7 expression was maintained in the anterior septal mesenchyme close to the elongating ducts (Fig. 5H) . These results suggest that MNG duct elongation may be reliant on FGF7 or another FGF ligand with high affinity to FGFR2 such as FGF1 and FGF22. Multiple FGFs may therefore compensate for the development of these glands. . (E) Similar development is seen in Fgf10 þ/ À littermates as the Steno's duct dips into the underlying mesenchyme at E12.5. At E17.5, the Steno's duct is found in Fgf10 þ/ À animals (F), and the distal gland has developed however a reduction in branching is evident (G -yellow). Reduced branching of the LNGs (G -green), MSG (G -red) and MNGs (H) is also observed in Fgf10þ / À embryos. (I) No Steno's ductal pit is found in the Fgf10 À / À mouse. An epithelial placode swelling occurs however, and development appears to arrest at this stage. At E17.5, the Steno's duct (J) and gland (K), and the MSG (K) are completely absent in the Fgf10 À / À animal. The LNG (K) and MNG (L) ducts extend to their correct location in the Fgf10 À / À however branching of the distal glands is severely defective. Steno's gland ¼yellow; MSG ¼red; LNG2 and 3¼ green; MNG¼ blue; asterisks represent absent gland. Column1 scale bar¼ 100 mm, Column2 scale bar¼ 50 mm, Column 3 and 4 scale bar¼ 100 mm.
EDA signalling is essential for LNG and MNG development
Histological analysis has previously indicated that some of the nasal glands are defective in Tabby mutant mice (Grüneberg, 1971) . We therefore decided to study the nasal glands of Eda Ta/Y male and Eda Ta/Ta female (Tabby) mice (referred to for simplicity as Eda Ta ) in more detail to compare to the Fgf mutants. Edar, encoding the receptor for EDA, was found to be expressed in the nasal gland epithelium during duct extension and branching (Fig. 6A-C) . Despite expressing components of the EDA pathway, the Steno's gland and MSG developed normally in Eda Ta mice (Fig. 6D-I) . Investigation of the LNG glands showed that only LNG3 and LNG8 develop in Eda Ta mutants, while no other ducts of the other LNGs were found either in the lateral nasal wall (Fig. 6J-K) or the middle conchal lip (Fig. 6L-M) . Similarly, to the Fgfr2b knockout mouse, LNG 4, beneath the nasal cartilage capsule, was absent in the Eda Ta mutant (Fig. 6N-O) . At a more rostral location, branching of LNG3 was observed to be severely defective in the Eda Ta mouse compared to WT littermates (Fig. 6P-Q) . Finally, the MNGs were completely absent in Eda Ta mice (Fig. 6R-S) .
Discussion
Fgf10 is essential for nasal gland branching morphogenesis
The anterior nasal glands provide a wonderful model for studying branching morphogenesis due to their prolonged duct elongation stage and subsequent gland branching. This allows the investigation of different pathways and signalling molecules involved in these distinct stages of organogenesis. In this study, it was elucidated that Fgf10 is essential for gland branching of all of the anterior nasal glands. Although branching of the glands occurs in an array of temporal locations, expression of Fgf10 mRNA was seen throughout the mesenchyme surrounding the gland end buds of all glands during their branching stages. This expression pattern of Fgf10 is similar to that observed during mammalian lung development where Fgf10 mRNA is localised to the mesenchyme surrounding newly developing lung buds (Bellusci et al., 1997) . In the lung, Fgf10 has been shown to trigger cell proliferation and act as a chemoattractant (Bellusci et al., 1997; Park et al., 1998) , and the expression pattern described in our study suggests a similar role in nasal SMG development. Examination of Fgf10 mutant mouse also emphasised that with one copy of Fgf10 present in the heterozygotes, branching of the nasal glands occurs however is reduced. In the complete absence of Fgf10 in the homozygotes, gland branching is seriously defective with only the presence of severely truncated end buds at the distal ductal tips. The heterozygous phenotype observed is consistent with the lacrimal gland and salivary gland aplasia present in the mouse model and human LADD syndrome (Entesarian et al., 2007; May et al., 2015) .
FGF10 plays a heterogeneous role in early anterior nasal gland development
The complete absence of the Steno's gland in the Fgf10 À / À mouse indicates this growth factor's pivotal role in the development of this structure. This gland differs from the other nasal glands as it buds approximately 24 h earlier and the duct bud invaginates into the mesenchyme as an epithelial indentation, as opposed to a solid swelling of cells (May and Tucker, 2015) . In this way the development is more akin to the development of the lung, where the lumen is an integral part of the invaginating epithelium, rather than the lacrimal or salivary glands, where the lumen forms later due to cavitation of a solid cord. The maxillary sinus gland is unusual in that it branches immediately from the maxillary sinus epithelium without formation of an extending duct, so here the loss of the gland is linked to the essential role of Fgf10 in branching morphogenesis. In contrast to these glands, the lateral nasal glands (LNG), despite expressing Fgf10 from early stages, had normal duct elongation in the Fgf10 À / À mice, while the medial nasal glands were also less severely affected. Due to the complexity of biological regulatory networks, removal of one or some of its elements does not necessarily contribute to its overall collapse Albert et al., 2000) . Therefore, other signalling molecules appear to compensate for the loss of FGF10.
Other signalling molecules are required for lateral and medial nasal gland development
The loss of the medial nasal glands in the Fgfr2b À / À mice indicate that another FGF, working through this receptor, is able to compensate for loss of FGF10. A likely candidate is FGF7. The amino acid core of FGF7 shows over 60% sequence identity with that of Fgf10, making it the most structurally similar growth factor to Fgf10 (Yamasaki et al., 1996) . Biological functions are also conserved between these two mesenchymally expressed Fgfs, emphasised by both the ligands having high affinity to FGFR2b. During mouse lung development, Fgf7 is not expressed in the lung mesenchyme during early endoderm branching at E11.5 however Fgf7 transcripts are detected when the lung is undergoing extensive branching between E13.5 and E14.5 (Bellusci et al., 1997) . Early studies using culture of mesenchyme-free endoderm with FGF7 protein showed that it stimulates endoderm stalk extension by inducing cell proliferation (Cardoso et al., 1997) . While Fgf7 expression was not as evident as that of Fgf10 in the periocular mesenchyme during normal in vivo lacrimal gland development, application of an FGF7 bead to lacrimal gland explant cultures induced ectopic gland bud formation, similarly to FGF10 protein application, however not at as high a rate (Makarenkova et al., 2000) . In comparison, culture of submandibular salivary glands with FGF7 only gave rise to moderate stalk extension and instead induced epithelial bud enlargement (Koyama et al., 2008) . The localisation of Fgf7 mRNA in the nasal septum mesenchyme from E14.5 to E15.5 when the MNG ducts are budding, elongating and beginning to branch suggest that Fgf7 function may be utilised by these developing glands in the absence of Fgf10. Fgf7 mutants do not display gland defects, suggesting that Fgf10 is able to compensate for loss of Fgf7 in those glands where both are expressed (Guo et al., 1996) . LNG2, LNG3 and LNG5 all bud and elongate as ducts to the presumptive branching location independent of FGFR2b signalling. Due to the abundant amount of lateral nasal glands found in both rodents and humans, understanding the development of these glands is important in elucidating causes of nasal conditions such as rhinitis and sinusitis. Interestingly the lateral nasal glands, with the exception of LNG3 and 8, failed to form in the Eda mutants, while LNG3 had severely reduced branching. These lateral glands therefore rely more heavily on the EDA pathway for their development, with the pathway being important for both duct development and branching. The medial nasal glands were also missing, similar to the Fgfr2b À / À . These glands therefore require both EDA and FGF signalling for their correct development.
From this study we want to emphasise that nasal SMGS not only adopt contrasting temporal locations and methods of development, they each employ different signalling factors and intracellular cues for their tightly controlled duct elongation and glandular branching. This is important as we can assume defects in different subsets of nasal glands in patients with LADD syndrome and HED. LADD syndrome is caused by mutations in one copy of Fgfr2b or Fgf10, therefore the heterozygous mice are a good model for this disorder. Importantly branching morphogenesis of all nasal glands was reduced in the Fgf10þ /À mice, suggesting that a similar reduction in branching would be found in the nasal glands of LADD patients. XL-HED is caused by complete loss of EDA function, and our results suggest that the lateral and medial nasal glands would be particularly affected in these patients. Such a dramatic loss of these key glands, which cannot be compensated by FGF signalling, would explain the reported defects in this region (Al-Jassim and Swift, 1996; Dietz et al., 2013) , although the anterior nasal gland (analogous to the Steno's gland) would be expected to form normally in HED patients.
